Edition:
United Kingdom

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

1.68USD
12 Dec 2017
Change (% chg)

$-0.05 (-2.89%)
Prev Close
$1.73
Open
$1.75
Day's High
$1.75
Day's Low
$1.55
Volume
144,318
Avg. Vol
316,337
52-wk High
$2.95
52-wk Low
$0.88

Latest Key Developments (Source: Significant Developments)

OncoSec Medical files for offering of up to 6.83 mln shares
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Oncosec Medical Inc -:OncoSec Medical Inc files for offering of up to 6.83 million shares of co's common stock by the selling shareholders - SEC filing.  Full Article

Oncosec announces positive follow-up data from phase 2 trial of Immunopulse il-12
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Oncosec Medical Inc :Oncosec announces positive updated long-term follow-up data from phase 2 trial of Immunopulse il-12 in combination with pembrolizumab demonstrating a progression free survival rate (PFS) of 57% at 15 months in predicted anti-pd-1 non-responder melanoma p.  Full Article

Oncosec appoints Daniel O'Connor as CEO
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Oncosec Medical Inc :Oncosec appoints Daniel J. O'Connor as chief executive officer to lead next stage of growth as a fully integrated late stage development and commercial company.Oncosec medical - ‍punit Dhillon, co-founder of Oncosec, will continue to serve as company's president and a member of its board​.  Full Article

Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - OncoSec Medical Inc :Intracoastal Capital LLC reports 7.5 pct passive stake in OncoSec Medical Inc, as of October 22, 2017‍​.  Full Article

OncoSec Q4 loss per share $0.28
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - OncoSec Medical Inc : :OncoSec announces fourth quarter and year end financial results for fiscal year 2017.Q4 loss per share $0.28.OncoSec medical - ‍expects current funds to be sufficient to allow co to continue to operate business to third calendar quarter of 2018​.  Full Article

Oncosec Medical Inc says has ‍initiated phase 2b registration directed trial, pisces/keynote-695
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Oncosec Medical Inc :Oncosec initiates registration directed clinical trial, keynote-695, of immunopulse® il-12 in combination with merck's keytruda® (pembrolizumab).Oncosec Medical Inc - ‍initiated phase 2b registration directed trial, pisces/keynote-695.  Full Article

Oncosec Q4 loss per share $0.39
Thursday, 13 Oct 2016 

Oncosec Medical Inc : Oncosec announces fourth quarter and year end results for fiscal year 2016 . Q4 loss per share $0.39 .Oncosec Medical Inc - Qtrly net loss $6.6 million versus $6.5 million.  Full Article

Oncosec posts Q3 loss per share $0.37
Thursday, 9 Jun 2016 

Oncosec Medical Inc : Oncosec announces third quarter and YTD results for fiscal year 2016 . Q3 loss per share $0.37 .Expects funds to be sufficient to allow it to continue to operate its business for at least next 12 months.  Full Article

BRIEF-OncoSec Medical files for offering of up to 6.83 mln shares

* OncoSec Medical Inc files for offering of up to 6.83 million shares of co's common stock by the selling shareholders - SEC filing Source: (http://bit.ly/2hEfpJ6) Further company coverage: